Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.33.
Rani Therapeutics Holdings Inc. (RANI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 193,300 | $264,821 | +8687% | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 118,966 | $162,983 | +343% | 0% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 110,163 | $150,923 | 0% | |
| 4. | Avenue Capital Marc Lasry | 62,887 | $86,155 | 0.38% | |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 10,863 | $14,882 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.67 | 17,960 | 17,960 | 2024-12-13 | Filing | ||
| $1.94 | 10,296 | 494,751 | 2024-12-09 | Filing | ||
| $2.01 | 5,265,165 | Large Shareholder | 12,131,554 | 2023-11-24 | Filing | |
| $2.27 | 10,000 | 484,455 | 2023-12-06 | Filing | ||
| $2.57 | 5,000 | 474,455 | 2023-12-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.26 | 523,738 | Large Shareholder | 8,302,194 | 2024-10-15 | Filing | |
| $2.55 | 3,305,622 | Large Shareholder | 8,825,932 | 2024-10-15 | Filing | |
| $2.01 | 5,265,165 | Large Shareholder | 8,400 | 2023-11-24 | Filing | |
| $11.62 | 9,210 | Director | 66,445 | 2022-08-17 | Filing | |
| $10.51 | 71,042 | Director | 75,655 | 2022-08-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 709,828 | $972,465 | 0% | |
| 2. | 493,584 | $676,210 | 0.57% | |
| 3. | 448,492 | $614,434 | 0.03% | |
| 4. | 302,743 | $414,758 | 0.01% | |
| 5. | 291,381 | $399,192 | 0% |
News See All
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call Transcript
Operator: Hello, and welcome to Rani Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are a in a listen-only mode.
8 Best Stocks to Buy According to Billionaire Marc Lasry
In this article, we will take a look at the 8 Best Stocks to Buy According to Billionaire Marc Lasry.
Billionaire Hedge Funds
